- 7.1.1. The Grantholder must comply with CR-UK’s policy on data sharing and preservation by ensuring that they submit a data management and sharing plan as part of their application. Please refer to our website for further details.
- 7.1.2. CR-UK requires Researchers to promulgate the results of the research that it funds in the usual manner, for example by publication and by presenting at meetings. CR-UK has the right to require publication to be delayed to meet reasonable requirements for the protection of Intellectual Property Rights, fundraising and other matters, but this will not be applied unnecessarily.
- 7.1.3. Before publication, the Host Institution must ensure the Research undergoes the Host Institution’s standard procedures for ensuring the validity of the results and the suitability of the research for general publication. CR-UK takes no responsibility for the validity of the Results or for any statements made by the authors in the publication.
- 7.1.4. Under UK charity law, CR-UK has an obligation to make available information about the work that it funds and will respond to changes in the way that information of this type is exchanged. It is a condition of funding that CR-UK Grantholders deposit an electronic copy of peer-reviewed, published papers arising from their CR-UK funded work in the UK PubMed Central database. Please refer to the CR-UK Policy on UK PubMed Central and Open Access.
- 7.1.5. Subject to any agreement between the Host Institution and CR-UK/ CRT, Grantholders are required to: i) consult CRT in accordance with Section 6.1.8; and (ii) seek the consent of the Drug Development Office before publication or other disclosure of any work relating to a DDO Project. Where a member of the DDO has contributed significantly to a publication, the DDO must be consulted as to whether this should be recognised in the list of authors. If the CR-UK Biotherapeutics Development Unit or Formulation Unit has been involved in development work or drug supply, all publications relating to the DDO Project must include a member of the relevant Unit in the list of authors.
- 7.1.6. Grantholders must provide Cancer Research UK with details of all publications arising from the CR-Research, whether wholly or partly funded. Details should be provided at the time of submission for publication to ensure that CR-UK is kept fully informed of all Results entering the public domain and has sufficient notice to arrange any publicity. Notification should be made via the online manuscript submission form available on the CR-UK website.
- 7.1.7. Details of all publications will also be required in the Annual Research Update Report.
- 7.1.8. Studies involving human subjects represent a special case, especially if the publication, either in print or electronic format, of the results enables individuals (the subjects or others) to gain knowledge about their personal condition which they otherwise would not have had. In any clinical study where this is possible the matter must be addressed in the protocol and discussed with a Research Ethics Committee.
- 7.1.9. Investigators must consider whether a mechanism is needed for human subjects to be made aware of the results and the implications for them personally before publication (communication with their GP or the consultant entering them into the trial, with a clear indication of their responsibility for communicating to the patient, would be deemed to be sufficient). If such a mechanism is put in place, there must also be procedures for dealing with any consequences arising from its use.
- 7.1.10. Researchers are reminded that electronically published descriptions of work which involves the use of animals will more easily be seen by those who may seek to misuse the information. Whilst CR-UK will always support appropriate animal experimentation, Researchers are requested to be cautious in what they write and especially to avoid the publication of photographs. If in doubt, Researchers should refer to the guidelines published by their Host Institution.
- 7.2.1. In any oral or written report or poster presentation of Results or otherwise relating to the Research, the author must acknowledge the support of CR-UK and, where possible, display the ‘funded by CR-UK’ logo. All references to CR-UK funded work placed on websites, electronic bulletin boards and similar must state clearly that the work is funded by CR-UK and, where practical, should include a link to CR-UK’s website, www.cancerresearchuk.org.
- 7.2.2. It is essential that investigators acknowledge that their research has been supported wholly or in part by CR-UK using the format, “This work was supported by CR-UK [grant number C ref./A ref.]”. All studies approved by the Clinical Trials Advisory and Awards Committee must also quote the CR-UK trial number (CR-UK ref).
- 7.3.1. In order to safeguard future voluntary income and maintain our reputation for world class science, it is essential that CR-UK is widely known and respected among the scientific community, the media and among fundraisers and the general public. All opportunities to promote CR-UK must therefore be fully exploited and Grantholder and the Host Institution are obliged to co-operate with CR-UK over any publicity or fundraising activity arising from CR-UK funded research. Where CR-UK is the main funder of the research, CR-UK reserves the right to lead on publicity. Grantholders and the Host Institution are required to contact the press office prior to any publicity releases about CR-UK funded research.
- 7.3.2. When speaking publicly about their research and particularly when speaking to representatives of the media, Researchers should ensure that they are recognised as a CR-UK funded scientist. However, Researchers should not speak to the media as a ‘Cancer Research UK funded scientist’ without prior consultation with the press office.
- 7.3.3. There is a subtle but important difference between speaking as a ‘Cancer Research CR-UK funded scientist’ and acting as a spokesperson for the charity, which Researchers are not authorised to do. Representatives of the media may not always be aware of this difference and Researchers who speak to the media must ensure that their personal views are not misrepresented as being attributable to CR-UK.
- 7.3.4. CR-UK reserves the right to use data or other material from research that it funds as part of its fundraising or publicity activities.
- 7.3.5. Grantholders are required to submit publishable information about their proposed research and limited publishable contact information at the time of application. If the application is funded, these details will be published on CR-UK’s website. A publishable abstract must be submitted for all successful awards and failure to submit will delay the activation of the award.
- 7.3.6. All disclosures of information regarding clinical trials funded by CR-UK to the media must be channelled through the Press Office, and, for Phase I/II trials, only after discussion with the Director of the Drug Development Office.
Increase text
Decrease text
Print this page